Prof. Max Herzberg, the Founder and Chairperson of the Board of Vidac Pharma, is a renowned scientist and entrepreneur and one of the founding fathers of the Israel life sciences industry. Prof. Herzberg founded Orgenics and the EagerBio Group, is the co-founder of PixCell, and served as chairperson of several Israeli biotechnology companies and as chairperson of the European Molecular Biology Laboratory Enterprise Management (Heidelberg, Germany). Prof. Herzberg holds a Ph.D. in Molecular Biology from the Weizmann Institute of Science.
Dr. Becker joined Vidac Pharmaceuticals as President and Chief Executive Officer in 2013. Dr. Becker brings more than 20 years of biopharmaceutical industry entrepreneurship and leadership experience to Vidac, with expertise in the discovery and development of innovative novel pharmaceuticals. Dr. Becker led or co-led more than $2B worth of deals with GSK, Amgen, Teva, Clevexel, and CFFT. Dr. Becker was a founder, Director and Chief Science Officer of Predix Pharmaceuticals (Lexington, MA and Ramat-Gan, Israel), a GPCR-focused neurology play, which was acquired by Epix Pharmaceuticals (NASDAQ:EPIX). Subsequently he served as the CSO of Epix. Under his leadership 5 novel drugs were discovered and introduced into clinical development (Phases 1 to 3). Dr. Becker was also the founder, Director and Chief Executive Officer of Dynamix Pharmaceuticals, a cancer and autoimmune drug discovery and development company, and is a co-founder and a member of the Board of Directors of Immunity Pharma, which is developing a novel drug for ALS. Dr. Becker was a professor at Tel-Aviv University and at Harvard University. He holds a PhD from the Hebrew University of Jerusalem, and a post-doctoral training from Harvard University. Dr. Becker has published more than 50 scientific papers, has co-edited two books, and is an inventor on numerous patents.
Former member of the Global Executive Comitte and Executive Vice-President of Sanofi in charge of diagnostic, agro-veterinary and capital development. Former Executive Vice-President of Institut Pasteur in charge of technology transfer. Former chairman of Cellectis. Presently seating in France, Israel, Belgium and USA at the boards of several Life Science Companies and Health Charities.
Founder and Manager and then Active Chairman of Orbotech from creation to $3.4B exit. . Mr. Richter was previously employed as a Founder by SeeRun Corp. He also served on the board at Photon Dynamics, Inc. He received his undergraduate degree from Technion-Israel Institute of Technology.
Dr. Robert Spiegel, who in 2016 joined Vidac’s board as an observer, is the former CMO of Schering Plough Corporation where he served as SVP worldwide clinical development and participated in over 30 NDAs. He is now an Associate Professor at Weill Cornell Medical School and serves as an Advisor to Warburg Pincus. He is a member of the Board of several private and public biotech companies and serves as the President of Spiegel Consulting LLC. He is a graduate of Yale University (B.A.) and University of Pennsylvania (M.D.) and completed his medical training as a Research Associate at the National Cancer Institute, NIH.